99455-05-7

Basic information

• Product Name: 6-bromo-2-methoxyquinoline
• Synonyms: 6-bromo-2-methoxyquinoline;6-Bromo-2-methoxyquinoline 95%;6-Bromo-2-methoxy-1-azanaphthalene;2-methoxy-6-bromoquinoline;Quinoline,6-bromo-2-methoxy-;6-Bromo-2-methoxyquinoline95%
• CAS NO: 99455-05-7
• Molecular Formula: C₁₀H₈BrNO
• Molecular Weight: 238.0806
• Mol File: 99455-05-7.mol
• Article Data: 14

Chemical Properties

• Melting Point: 87-89℃
• Boiling Point: 312.635 °C at 760 mmHg
• Flash Point: 142.877 °C
• Appearance: /
• Density: 1.517 g/cm³
• PKA: 2.39±0.43(Predicted)
• CAS DataBase Reference: 6-bromo-2-methoxyquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-2-methoxyquinoline(99455-05-7)
• EPA Substance Registry System: 6-bromo-2-methoxyquinoline(99455-05-7)

Safety Data

• Hazardous Substances Data: 99455-05-7(Hazardous Substances Data)

Usage

Uses

6-Bromo-2-methoxyquinoline is a reagent used for preparing diarylquinoline derivatives.

Upstream product

• 67-56-1 methanol 
• 1810-71-5 6-bromo-2-chloroquinoline 
• 6563-11-7 6-bromoquinoline-N-oxide 
• 5332-25-2 6-bromoquinoline 
• 2971-79-1 isonipecotic acid methyl ester 
• 124-41-4 sodium methylate 
• 89446-46-8 6-bromo-2-chloro-4,8-dimethyl-quinoline 
• 1810-66-8 6-bromo-2-quinolone 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 327058-51-5 N-(4-bromophenyl)-(E)-3-ethoxyacrylamide 
• 106-40-1 4-bromo-aniline 
• 6931-16-4 2-methoxy-quinoline 

Downstream Products

• 327057-63-6 N,N-diisobutyl-4-(2-methoxy-quinolin-6-yl)-benzamide 
• 327057-70-5 N,N-dicyclohexyl-4-(2-methoxy-quinolin-6-yl)-benzamide 
• 99455-21-7 6-(2,6-Dimethyl-pyridin-3-yl)-2-methoxy-quinoline 

Relevant articles and documents

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Synthesis and biological evaluation of 2-substituted quinoline 6-carboxamides as potential mGluR1 antagonists for the treatment of neuropathic pain

A series of 2-amino and 2-methoxy quinoline-6-carboxamide derivatives have been synthesized and their metabotropic glutamate receptor type 1 (mGluR1) antagonistic activities were evaluated in a functional cell-based assay. The compound 13c showed the highest potency with IC50 value of 2.16μM against mGluR1. Finally, in vivo evaluation of 13c in the rat spinal nerve ligation (SNL) model exhibited weak analgesic effects with regard to both mechanical allodynia and cold allodynia.

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.